An article in Forbes reports on new findings that show ImClone Systems' colon cancer drug Erbitux and a similar drug from Amgen, Vectibix, may not work in half of colon cancer patients. By using a genetic test, it can tell patients whether they have tumors with a mutation in kras that would make the drugs ineffective.